



Sheet 1 of 1

#5  
3/19/00  
82

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:  
PD0873Q4SERIAL NO.:  
09/899,764APPLICANT:  
Farah J. MUNAYYER et al.FILING DATE:  
July 5, 2001GROUP:  
1624

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RR	AA	4,659,716	4/21/87	Villani et al.	514	290	
RR	AB	4,783,465	11/08/88	Sunshine et al.	514	255	
RR	AC	4,975,426	12/4/90	Sunshine et al.	514	159	
RR	AD	5,759,579	6/2/98	Singh et al.	424	485	
RR	AE	5,912,007	6/15/99	Pan et al.	424	440	
RR	AF	5,939,426	8/17/99	McCullough	514	290	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
RR	AG	0 620 001 A1	10/19/94	Europe				
RR	AH	WO 98/18470	5/7/98	WIPO				
RR	AI	WO 98/24414	6/11/98	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	AJ	Drug Facts and Comparisons, 1998 Ed., Facts and Comparisons, St. Louis, Missouri, p. 2832						
RR	AK	The United States Pharmacopeia, The United States Formulary, United States Pharmacopeial Convention, Inc., Rockville, Maryland, 1989, p. 1990.						
RR	AL	Remington's Pharmaceutical Sciences, 18 <sup>th</sup> Ed., Mack Publishing Company, Easton, Pennsylvania, 1990, pp. 1519-1520 and 1527-1529.						

EXAMINER

R Raymon

DATE CONSIDERED

9-5-02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.